tailieunhanh - Danh mục thuốc thiết yếu của Tổ chức y tế thế giới

The core list presents a list of minimum medicine needs for a basic health‐care system, listing the most efficacious, safe and cost‐effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost‐effective treatment. The complementary list presents essential medicines for priority diseases, for which specialized diagnostic or monitoring facilities, and/or specialist medical care, and/or specialist training are needed. In case of doubt medicines may also be listed as complementary on the basis of consistent higher costs or less attractive costeffectiveness in a variety of settings | WHO Model List of Essential Medicines 17th list March 2011 Status of this document This is a reprint of the text on the WHO Medicines web site http medicines publications essentialmedicines en The published material is being distributed without warranty of any kind either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. 17th edition Essential Medicines WHO Model List March 2011 Explanatory Notes The core list presents a list of minimum medicine needs for a basic health-care system listing the most efficacious safe and cost-effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance and potential for safe and cost-effective treatment. The complementary list presents essential medicines for priority diseases for which specialized diagnostic or monitoring facilities and or specialist medical care and or specialist training are needed. In case of doubt medicines may also be listed as complementary on the basis of consistent higher costs or less attractive costeffectiveness in a variety of settings. The square box symbol is primarily intended to indicate similar clinical performance within a pharmacological class. The listed medicine should be the example of the class for which there is the best evidence for effectiveness and safety. In some cases this may be the first medicine that is licensed for marketing in other instances subsequently licensed compounds may be safer or more effective. Where there is no difference in terms of efficacy and safety data the listed medicine should be the one that is generally available at the lowest price based on international drug price information sources. Not all square boxes are applicable to medicine selection for children see the second EMLc for details. Therapeutic .